Literature DB >> 16423090

Twice-a-day quadruple therapy for eradication of Helicobacter pylori in the elderly.

Maria Pina Dore1, Emmanouil Maragkoudakis, Antonella Pironti, Vincenza Tadeu, Rinaldo Tedde, Giuseppe Realdi, Giuseppe Delitala.   

Abstract

BACKGROUND: Midday and evening twice-a-day quadruple therapy appears to be the most effective therapy for Helicobacter pylori infection in Northern Sardinia, a site where antibiotics resistance is common. AIM: The objective of our study was to estimate the efficacy, side-effects, and compliance of a quadruple therapy containing esomeprazole in a group of dyspeptic elderly patients. PATIENTS AND METHODS: Consecutive elderly patients positive for H. pylori infection and not previously treated for eradication were enrolled. Therapy consisted of esomeprazole 20 mg, tetracycline 500 mg, metronidazole 500 mg, and bismuth subcitrate tablets 240 mg, all twice-a-day with the midday and evening meals, for 10 days. Efficacy was evaluated using 13C-urea breath testing. Compliance was assessed after completing treatment and at follow up. Side effects were graded based on daily activities.
RESULTS: Ninety-five dyspeptic patients (range 65-81 years), 52 men and 43 women, were enrolled. The intention-to-treat cure rate was 91% (81 of 89; 95% CI = 88-99%) and, 95% (81 of 85; 95% CI = 83-96%) per-protocol analysis. Compliance was excellent. Mild-moderate side effects occurred in 27 patients.
CONCLUSIONS: Esomeprazole containing quadruple therapy was highly successful for initial eradication of H. pylori in elderly patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16423090     DOI: 10.1111/j.0083-8703.2006.00370.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  9 in total

Review 1.  How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.

Authors:  David Y Graham; Sun-Young Lee
Journal:  Gastroenterol Clin North Am       Date:  2015-06-19       Impact factor: 3.806

2.  Helicobacter pylori Therapy in the West.

Authors:  David Y Graham; Emiko Rimbara
Journal:  Jpn J Helicobacter Res       Date:  2012

3.  Empiric H. pylori therapy-10-day concomitant, bismuth quadruple or 14-day triple therapy: none is best.

Authors:  Yoshio Yamaoka; David Y Graham
Journal:  Transl Cancer Res       Date:  2016-12       Impact factor: 1.241

Review 4.  Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China.

Authors:  Hong Lu; Wei Zhang; David Y Graham
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-10       Impact factor: 2.566

5.  Comparison of short- and long-term treatment protocols and the results of second-line quadruple therapy in children with Helicobacter pylori infection.

Authors:  Yusuf Usta; Inci Nur Saltik-Temizel; Hulya Demir; Nuray Uslu; Hasan Ozen; Figen Gurakan; Aysel Yuce
Journal:  J Gastroenterol       Date:  2008-07-04       Impact factor: 7.527

Review 6.  Helicobacter pylori infection in older people.

Authors:  Alberto Pilotto; Marilisa Franceschi
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

7.  Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence.

Authors:  David Y Graham; Yi-Chia Lee; Ming-Shiang Wu
Journal:  Clin Gastroenterol Hepatol       Date:  2013-06-08       Impact factor: 11.382

8.  Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series.

Authors:  Maria P Dore; Sara Soro; Chiara Rocchi; Maria F Loria; Stefano Bibbò; Giovanni M Pes
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

9.  Helicobacter pylori eradication therapy: A review of current trends.

Authors:  A B Olokoba; O A Obateru; M O Bojuwoye
Journal:  Niger Med J       Date:  2013-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.